Anti-Toxoplasma gondii antibodies in hemodialysis patients receiving long-term hemodialysis therapy in Turkey

Saudi Medical Journal

Volumn 26, Issue 9, 2005, Pages 1378-1382

  Ocak, Sabahattin ^a   Duran, Nizami ^a,c   Eskiocak, Ali F ^a   Aytac, Hasip ^b  

^a MUSTAFA KEMAL UNIVERSITY   (Turkey)

^b ANTAKYA STATE HOSPITAL   (Turkey)

^c Gullu Bahce Mahallesi   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G;

ADULT; AGED; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE TRANSMISSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODIALYSIS; HUMAN; INFECTION RISK; KIDNEY FAILURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; POPULATION DISTRIBUTION; POPULATION RESEARCH; SERODIAGNOSIS; SEROPREVALENCE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TOXOPLASMA GONDII; TOXOPLASMOSIS; TURKEY (REPUBLIC);

ADULT; AGED; ANIMALS; ANTIBODIES, PROTOZOAN; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; KIDNEY FAILURE, CHRONIC; LONG-TERM CARE; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDIES; REFERENCE VALUES; RENAL DIALYSIS; RISK ASSESSMENT; TOXOPLASMA; TOXOPLASMOSIS; TURKEY;

EID: 26944435481     PISSN: 03795284     EISSN: 03795284     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Dubey JP, Lindsay DS, Speer CA. Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. Clin Microbiol Rev 1998; 11: 267-299.
2. Aydemir M, Yorgancigil B, Demirci M. Prevalence of toxoplasma IgG and IgM antibodies in haemodialysis patients. Acta Parasitologica Turcia1996; 20: 311-315.
3. Bahar IH, Yücesoy M, Yulug N. Prevalence of toxoplasma antibodies in haemodialysis patients. Acta Parasitologica Turcia 1994; 18: 409-414.
4. Asci Z, Seyrek A, Kizirgil A, Doymaz MZ, Yilmaz M. Toxoplazma supheli hasta serumlarinda anti-Toxoplasma gondii IgG ve IgM antikorlarinin arastirilmasi. Turkiye Parazitoloji Dergisi 1997; 21: 245-247.
5. Altintas N, Kuman HA, Akisu C, Aksoy U, Atambay M. Toxoplasmosis in last four years in Agean region, Turkey. J Egypt Soc Parasitol 1997; 27: 439-443.
6. Ustun S, Aksoy U, Dagci H, Ersoz G. Incidence of toxoplasmosis in patients with cirrhosis. World J Gastroenterol 2004; 10: 452-454.
7. Yazar S, Demirtas F, Yalcin S, Yaman O, Tokgoz B, Utas C, et al. Anti-Toxoplasma gondii antibodies in haemodialysis patients with chronic renal failure. Yonsei Med J 2003; 44: 288-292.
8. Garcia SL, Bruckner AD. Parasitic infections in the compromised host (Toxoplasma gondii). In: Garcia SL, Bruckner AD, editors. Diagnostic Medical Parasitology, 3th ed. Washington (DC): American Society for Microbiology; 1997. p. 423-424.
9. Langhoff E, Ladefoyed J. In vitro immune function in patients with minor, moderate and severe kidney impairment. APMIS 1988; 96: 655-659.
10. Abbas MM, Zaki M, Afify NA. Prevalence of Toxoplasma gondii and cytomegalovirus antibodies in patients with chronic renal failure. J Egypt Soc Parasitol 1996; 26: 671-676.
11. Le Blanc O, Campbell SM, Honee C. Haemodynamics of choronic renal failure. Br Med J 1989; 24: 974-976.
12. Butter KT. Infections in renal failure. J Infect Dis 1992; 12: 325-328.
13. Beaman MH, Mccabe RE, Wong S, Remington JS. Toxoplasma gondii. In Principles and Practice of Infections Diseases. Mandell GL, Benett JE, Dolin R, editors. 4th ed. New York: Churchill Livingstone; 1995. p. 2393-2525.
14. Frenkel JK. Toxoplasmosis. In: Gilles HM, editor, Protozoal Diseases. New York: Arnold Publishers; 1991. p. 530-547.
15. Heyneman D. Medical parasitology. In: Jawez E, Melnick JL, Adelberg EA, editors. Medical Microbiology. New Jersey: Appleton and Lange; 1991. p. 332-365.
16. Montaya JG, Remington JS. Toxoplasma gondii. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. Philadelphia: Churchill Livingstone; 2000. p. 2858-2881.
17. Malaponte G, Bevelacqua V, Fatuzzo P, Rapisarda F, Emmanuele G, Travali S, et al. IL-Ibeta, TNF-alpha and IL-6 release from monocytes in haemodialysis patients in relation to dialytic age. Nephrol Dial Transplant 2002; 17: 1964-1970.
18. Gutierrez J, Roldan C, Maroto MC. Seroprevalence of human toxoplasmosis. Microbios 1996; 85: 73-75.
19. Wang BL, Pan XZ, Yin YK, Weng XH. Investigation of anti-Toxoplasma gondii antibodies in immunodeficient patients. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2000; 18: 224-226.
20. Galvan Ramirez ML, Valdez Alvarado V, Vargas Gutierrez G, Jimenez Gonzalez O, Garcia Cosio C, Vielma Sandoval M. Prevalence of IgG and IgM anti-Toxoplasma antibodies in patients with HIV and acquired immunodeficiency syndrome (AIDS). Rev Soc Bras Med Trop 1997; 30: 465-467.
21. Eleftheriadis T, Papazisis K, Kortsaris A, Vayonas G, Voyatzi S, Vargemezis V. Impaired T cell proliferation and zeta chain phosphorylation after stimulation with staphylococcal enterotoxin-B in haemodialysis patients. Nephron Clin Pract 2004; 96: 15-20.
22. Riemsdijk IC, Baan CC, Loonen EH, Zietse R, Weimar W. Patients on chronic haemodialysis have no intrinsic lymphocyte defect upon stimulation with interleukin-2, interleukin-1 or tumor necrosis factor-alpha. Blood Putif 2003; 21: 158-162.
23. Girndt M, Sester M, Sester U, Kaul H, Kohler H. Molecular aspects of T-and B-cell function in uremia. Kidney Int 2001; 59: 206-211.